These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 821489)

  • 1. Effect of carbidopa on the metabolism of L-dopa in the pigtail monkey.
    Bronaugh RL; Wenger GR; Garver DL; Rutledge CO
    Biochem Pharmacol; 1976 Jul; 25(14):1679-81. PubMed ID: 821489
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of pyridoxine on the depletion of tissue pyridoxal phosphate by carbidopa.
    Airoldi L; Watkins CJ; Wiggins JF; Wurtman RJ
    Metabolism; 1978 Jul; 27(7):771-9. PubMed ID: 661563
    [No Abstract]   [Full Text] [Related]  

  • 4. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
    Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R
    DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
    Rose S; Jenner P; Marsden CD
    Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
    Goodale DB; Moore KE
    Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic administration does not alter the pharmacokinetic profile of L-dopa in the rat.
    Rose S; Jenner P; Marsden CD
    J Pharm Pharmacol; 1993 Aug; 45(8):725-30. PubMed ID: 7901371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition.
    Sandler M; Johnson RD; Ruthven CR; Reid JL; Calne DB
    Nature; 1974 Feb; 247(5440):364-6. PubMed ID: 4817854
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of L-dopa with and without decarboxylase inhibitor on growth hormone secretion in children with short stature.
    Fevang FO; Stoa RF; Thorsen T; Aarskog D
    Acta Paediatr Scand; 1977 Jan; 66(1):81-4. PubMed ID: 831384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of L-alpha-methyl-alpha-hydrazino-3,4 dihydroxyphenylpropionic acid with dopa-decarboxylase from pig kidney.
    Borri-Voltattorni C; Minelli A; Borri P
    FEBS Lett; 1977 Mar; 75(1):277-80. PubMed ID: 852589
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of the dopa decarboxylase inhibitor MK-486 on L-dopa-induced inhibition of prolactin secretion: evidence for CNS participation in the L-dopa effects.
    Szabo M; Nakawatase C; Kovathana N; Frohman LA
    Neuroendocrinology; 1977; 24(1):24-34. PubMed ID: 600362
    [No Abstract]   [Full Text] [Related]  

  • 13. [HGH secretion after oral application of L-dopa and L-carbidopa (author's transl)].
    Schönberger W; Ziegler R; Brodt B; Grimm W
    Eur J Pediatr; 1976 Jun; 122(3):195-200. PubMed ID: 1278188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of carbidopa and L-dopa combination on the secretion of growth hormone in normal subjects and in patients with Parkinsonism].
    Nurzia A; Vacca U; Pirro R; Cerone G
    Clin Ter; 1975 Aug; 74(3):265-70. PubMed ID: 1227747
    [No Abstract]   [Full Text] [Related]  

  • 16. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
    Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
    Drugs; 1976; 11(5):329-77. PubMed ID: 782834
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours.
    Jones MK; Ramsay ID; Jenner PG
    Br J Clin Pharmacol; 1978 May; 5(5):425-30. PubMed ID: 656281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism.
    Melamed E; Hefti F; Bitton V; Globus M
    Neurology; 1984 Dec; 34(12):1566-70. PubMed ID: 6504328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Action of phenytoin, ethosuximide and of the carbidopa-L-dopa association in semi-chronic cobalt-induced epilepsy in the rat.
    Scuvee-Moreau J; Lepot M; Brotchi J; Gerebtzoff MA; Dresse A
    Arch Int Pharmacodyn Ther; 1977 Nov; 230(1):92-9. PubMed ID: 603313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.